CLINICAL TRIAL: ACR16 VS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON'S D

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：评价ACR16对症治疗亨廷顿病(HD)的疗效，并探讨ACR16的量效关系。主要目的是评估ACR16对HD患者自主运动功能的影响。次要目标是评估ACR16在治疗12周时对临床总体变化印象(CGI-C)、认知功能、行为以及抑郁和焦虑症状的影响；此外，还评估其安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the effectiveness of ACR16 as a symptomatic treatment for Huntington disease (HD) and to investigate the dose-response relationship of ACR16. The primary objective is to assess the effects of ACR16 on voluntary motor function in HD subjects. Secondary objectives are to assess the effects of ACR16 on clinical global impression of change (CGI-C), cognitive function, behavior, and symptoms of depression and anxiety at 12 weeks of treatment; in addition to assessing its safety and tolerability.